Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease

Immunology Letters

Volumn 112, Issue 1, 2007, Pages 30-38

  Kim, Hong Duck ^a   Jin, Jing Ji ^a   Maxwell, J Adam ^a   Fukuchi, Ken ichiro ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Adenovirus; Alzheimer's disease; DNA vaccine; IL 10; IL 4; Prime boost strategies

Indexed keywords

AMYLOID BETA PEPTIDE[1-6]; AMYLOID BETA PROTEIN; DNA VACCINE; PLASMID DNA; UNCLASSIFIED DRUG;

ADENOVIRUS; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; LEARNING DISORDER; MEMORY DISORDER; MENINGOENCEPHALITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH2 CELL; VACCINATION;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODY FORMATION; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; TH2 CELLS; TIME FACTORS; TRANSFECTION; VACCINES, DNA;

EID: 34548203883     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.06.006     Document Type: Article

References (63)

1. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
2. Klafki H.W., Staufenbiel M., Kornhuber J., and Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 129 (2006) 2840-2855
3. Nitsch R.M. Immunotherapy of Alzheimer disease. Alzheimer Dis Assoc Disord 18 (2004) 185-189
4. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
5. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
6. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
7. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61 (2003) 46-54
8. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9 (2003) 448-452
9. Ferrer I., Boada R.M., Sanchez Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid β immunization in Alzheimer's disease. Brain Pathol 14 (2004) 11-20
10. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
11. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
12. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 (2005) 129-131
13. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6 (2000) 916-919
14. Monsonego A., and Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 302 (2003) 834-838
15. Gelinas D.S., DaSilva K., Fenili D., George-Hyslop P., and McLaurin J. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 101 (2004) 14657-14662
16. Goni F., and Sigurdsson E.M. New directions towards safer and effective vaccines for Alzheimer's disease. Curr Opin Mol Ther 7 (2005) 17-23
17. Schenk D., Hagen M., and Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 16 (2004) 599-606
18. Wisniewski T., and Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol 15 (2005) 72-77
19. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid. Int Immunol 15 (2003) 505-514
20. Ghochikyan A., Mkrtichyan M., Petrushina I., Movsesyan N., Karapetyan A., Cribbs D.H., et al. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch. Vaccine 24 (2006) 2275-2282
21. Agadjanyan M.G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174 (2005) 1580-1586
22. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., et al. Dendrimeric Aβ1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging 28 (2007) 813-823
23. Ghochikyan A., Vasilevko V., Petrushina I., Movsesyan N., Babikyan D., Tian W., et al. Generation and characterization of the humoral immune response to DNA immunization with a chimeric β-amyloid-interleukin-4 minigene. Eur J Immunol 33 (2003) 3232-3241
24. DaSilva K., Brown M.E., Westaway D., and McLaurin J. Immunization with amyloid-β using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. Neurobiol Dis 23 (2006) 433-444
25. 1-42 in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Aβ. Vaccine 24 (2006) 2824-2834
26. Ghochikyan A., Petrushina I., Lees A., Vasilevko V., Movsesyan N., Karapetyan A., et al. Aβ-immunotherapy for Alzheimer's disease using mannan-amyloid-beta peptide immunoconjugates. DNA Cell Biol 25 (2006) 571-580
27. Maier M., Seabrook T.J., and Lemere C.A. Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Vaccine 23 (2005) 5149-5159
28. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48 (2000) 567-579
29. Hsu C.T., Ting C.Y., Ting C.J., Chen T.Y., Lin C.P., Whang-Peng J., et al. Vaccination against gonadotropin-releasing hormone (GnRH) using toxin receptor-binding domain-conjugated GnRH repeats. Cancer Res 60 (2000) 3701-3705
30. Kim H.D., Maxwell J.A., Kong F.K., Tang D.C., and Fukuchi K. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Aβ1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem Biophys Res Commun 336 (2005) 84-92
31. 9 mouse model of Alzheimer's disease. J Gene Med 9 (2007) 88-98
32. Qu B., Rosenberg R.N., Li L., Boyer P.J., and Johnston S.A. Gene vaccination to bias the immune response to amyloid-β peptide as therapy for Alzheimer disease. Arch Neurol 61 (2004) 1859-1864
33. Okura Y., Miyakoshi A., Kohyama K., Park I.K., Staufenbiel M., and Matsumoto Y. Nonviral Aβ DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci USA 103 (2006) 9619-9624
34. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8 + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4 (1998) 397-402
35. Woodland D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25 (2004) 98-104
36. Prud'homme G.J. DNA vaccination against tumors. J Gene Med 7 (2005) 3-17
37. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95 (1998) 2509-2514
38. Zeng M., Smith S.K., Siegel F., Shi Z., Van Kampen K.R., Elmets C.A., et al. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. Biotechniques 31 (2001) 260-262
39. Kim H.D., Cao Y., Kong F.K., Van Kampen K.R., Lewis T.L., Ma Z., et al. Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid β-protein and GM-CSF. Vaccine 23 (2005) 2977-2986
40. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum Mol Genet 13 (2004) 159-170
41. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 (2006) 469-476
42. Meng W.S., Butterfield L.H., Ribas A., Dissette V.B., Heller J.B., Miranda G.A., et al. α-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 61 (2001) 8782-8786
43. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77 (2003) 8729-8735
44. Matsui M., Moriya O., and Akatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 21 (2003) 1629-1639
45. Mennuni C., Calvaruso F., Facciabene A., Aurisicchio L., Storto M., Scarselli E., et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 117 (2005) 444-455
46. Xin K.Q., Jounai N., Someya K., Honma K., Mizuguchi H., Naganawa S., et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 12 (2005) 1769-1777
47. Wu L., Kong W.P., and Nabel G.J. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 79 (2005) 8024-8031
48. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79 (2005) 9694-9701
49. Wilson N.A., Reed J., Napoe G.S., Piaskowski S., Szymanski A., Furlott J., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 80 (2006) 5875-5885
50. + responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera. Virology 323 (2004) 220-232
51. Tritel M., Stoddard A.M., Flynn B.J., Darrah P.A., Wu C.Y., Wille U., et al. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol 171 (2003) 2538-2547
52. McConnell M.J., Hanna P.C., and Imperiale M.J. Adenovirus-based Prime-boost immunization for rapid vaccination against anthrax. Mol Ther 15 (2007) 203-210
53. Rollier C., Verschoor E.J., Paranhos-Baccala G., Drexhage J.A., Verstrepen B.E., Berland J.L., et al. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. J Infect Dis 192 (2005) 920-929
54. Xin K.Q., Ooki T., Jounai N., Mizukami H., Hamajima K., Kojima Y., et al. A DNA vaccine containing inverted terminal repeats from adeno-associated virus increases immunity to HIV. J Gene Med 5 (2003) 438-445
55. Miralles V.J., Cortes P., Stone N., and Reinberg D. The adenovirus inverted terminal repeat functions as an enhancer in a cell-free system. J Biol Chem 264 (1989) 10763-10772
56. Klinman D.M. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 25 (2006) 135-154
57. Krieg A.M. Development of TLR9 agonists for cancer therapy. J Clin Invest 117 (2007) 1184-1194
58. Krieg A.M., Wu T., Weeratna R., Efler S.M., Love-Homan L., Yang L., et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 95 (1998) 12631-12636
59. Spies B., Hochrein H., Vabulas M., Huster K., Busch D.H., Schmitz F., et al. Vaccination with plasmid DNA activates dendritic cells via toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 171 (2003) 5908-5912
60. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., and Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42 (1992) 631-639
61. Nicoll J.A., Barton E., Boche D., Neal J.W., Ferrer I., Thompson P., et al. Aβ species removal after Aβ42 immunization. J Neuropathol Exp Neurol 65 (2006) 1040-1048
62. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., and LaFerla F.M. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 (2004) 321-332
63. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., and LaFerla F.M. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281 (2006) 39413-39423